Inaticabtagene Autoleucel

纳基奥仑赛

Report date: 2026/03/06 20:02:51

Base Information

Drug NameInaticabtagene Autoleucel
Drug Alias Name赫基仑赛Anti-CD19 chimeric antigen receptor T cell therapy (Juventas)源瑞达CNCT19CNCT-19 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsIron deficiencyLarge B Cell LymphomaLupus Erythematosus, Systemic +[15] 
Global Approved IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/11/08
Country/TerritoryUnited StatesMacauMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJuventas Cell Therapy Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Heyuan Biological Medicine Co LtdVcanbio Cell & Gene Engineering Corp LtdPeking Union Medical College Hospital +[6] 
Inactive CompaniesShandong University
Active IndicationsLarge B Cell LymphomaLupus Erythematosus, SystemicThrombocytopenia +[13] 
Inactive IndicationsIron deficiencyHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A